Sepsis with Negative Cultures – How Far to Investigate: A Comprehensive Approach to Culture-Negative Sepsis, Viral Sepsis, and Sepsis Mimics

Dr Neeraj Manikath , claude.ai

Abstract

Culture-negative sepsis represents a significant diagnostic challenge in critical care, accounting for 30-60% of suspected sepsis cases. This review provides a systematic approach to investigating patients with clinical sepsis syndrome but negative conventional cultures, emphasizing the differentiation between true culture-negative bacterial sepsis, viral sepsis, and non-infectious sepsis mimics including hemophagocytic lymphohistiocytosis (HLH). We present evidence-based diagnostic strategies, advanced microbiological techniques, and practical decision-making algorithms for the critical care physician.

Keywords: Culture-negative sepsis, viral sepsis, hemophagocytic lymphohistiocytosis, molecular diagnostics, sepsis mimics

Learning Objectives

After reading this review, the reader should be able to:

Recognize the clinical patterns of culture-negative sepsis and its key differentials
Implement a systematic diagnostic approach using advanced microbiological techniques
Differentiate between infectious and non-infectious causes of sepsis syndrome
Apply evidence-based criteria for diagnosing viral sepsis and HLH
Make informed decisions about antibiotic stewardship in culture-negative cases

Introduction

The clinical syndrome of sepsis with negative cultures presents one of the most challenging diagnostic dilemmas in critical care medicine. With mortality rates comparable to culture-positive sepsis (20-30%), the urgency of accurate diagnosis cannot be overstated. The term "culture-negative sepsis" encompasses a heterogeneous group of conditions ranging from true bacterial infections with fastidious organisms to viral infections and non-infectious inflammatory syndromes.

Recent advances in molecular diagnostics, biomarker development, and our understanding of host-pathogen interactions have revolutionized the approach to these complex cases. This review provides a comprehensive framework for investigation, emphasizing practical decision-making tools for the bedside clinician.

Epidemiology and Clinical Significance

Culture-negative sepsis accounts for 30-60% of clinically diagnosed sepsis cases, with higher rates observed in:

Patients with prior antibiotic exposure (up to 80% culture-negative rate)
Immunocompromised hosts
Cases with atypical presentations
Pediatric populations (up to 70% culture-negative rate)

The economic burden is substantial, with prolonged ICU stays averaging 2-3 days longer than culture-positive cases due to diagnostic uncertainty and empirical treatment strategies.

Pathophysiology: Understanding the Mechanisms

True Culture-Negative Bacterial Sepsis

Several mechanisms explain negative cultures in genuine bacterial infections:

Pre-analytical factors:
- Prior antibiotic administration (most common cause)
- Inadequate sample volume (<10mL for blood cultures)
- Delayed processing (>6 hours)
- Inappropriate transport conditions
Fastidious organisms:
- Slow-growing bacteria (Brucella, Bartonella, HACEK group)
- Cell-wall deficient bacteria (L-forms)
- Intracellular pathogens (Coxiella, Chlamydia)
Technical limitations:
- Standard culture media inadequacy
- Prolonged incubation requirements
- Specialized growth conditions needed

Viral Sepsis Syndrome

Viral infections can present with sepsis-like syndromes through:

Direct cytopathic effects
Immune dysregulation and cytokine storm
Secondary bacterial infections
Hemophagocytic activation

Common viral causes include influenza, COVID-19, CMV, EBV, HSV, and adenovirus.

Clinical Assessment Framework

Pearl #1: The "Culture-Negative Sepsis Triad"

Look for: (1) Clinical sepsis syndrome, (2) Negative cultures at 48-72 hours, (3) Response to antimicrobials OR alternative diagnosis identified.

Initial Clinical Evaluation

A systematic approach should include:

History and Physical Examination:

Timeline of symptom onset
Travel history and geographical exposures
Animal contacts and vector exposures
Occupational risks
Sexual history
Prior hospitalizations and antibiotic use
Family history of immunodeficiency or autoinflammatory conditions

Key Clinical Patterns:

Acute presentation with rapid deterioration: Consider viral sepsis (influenza, COVID-19) or HLH
Subacute course with fever and constitutional symptoms: Think fastidious bacteria or viral infections
Recurrent episodes: Consider autoinflammatory syndromes or immunodeficiency

Oyster #1: Beware of the "Too Well" Patient

Patients with culture-negative sepsis who appear relatively well despite meeting sepsis criteria may have non-infectious mimics or viral infections rather than bacterial sepsis.

Diagnostic Approach: The Systematic Investigation

Tier 1: Initial Extended Microbiology

Enhanced Blood Culture Techniques:

Lysis-centrifugation systems for mycobacteria and fungi
Resin-containing bottles for antibiotic removal
Extended incubation (up to 21 days for fastidious organisms)

Rapid Molecular Diagnostics:

Blood PCR panels (bacterial, viral, fungal)
Multiplex PCR for respiratory pathogens
16S rRNA gene sequencing for bacterial identification

Biomarkers for Bacterial vs. Non-Bacterial Differentiation:

Procalcitonin (PCT): >0.5 ng/mL suggests bacterial infection
C-reactive protein (CRP): Less specific but useful for trending
Presepsin: Emerging biomarker with high specificity
Neutrophil CD64: Rapid test for bacterial infections

Hack #1: The "72-Hour Rule"

If PCT remains >2 ng/mL at 72 hours with negative cultures, strongly consider:

Fastidious bacterial pathogens
Biofilm-associated infections
Intracellular organisms
Non-infectious inflammatory conditions

Tier 2: Advanced Microbiological Testing

Specialized Culture Techniques:

Mycoplasma/Chlamydia cultures
Legionella culture on BCYE agar
Francisella tularensis (notify laboratory)
Q fever (Coxiella burnetii) serology

Molecular Diagnostics:

Metagenomic next-generation sequencing (mNGS)
Targeted PCR for specific pathogens based on clinical suspicion
Mass spectrometry (MALDI-TOF) for rapid identification

Serological Testing:

Acute and convalescent sera for atypical pathogens
Specific IgM/IgG patterns
Cold agglutinins for Mycoplasma

Tier 3: Investigating Non-Infectious Causes

When bacterial and common viral causes are excluded, consider:

Hemophagocytic Lymphohistiocytosis (HLH):

HScore calculator (>169 suggests HLH)
Ferritin >500 µg/L (often >3000 µg/L in HLH)
Triglycerides >265 mg/dL
Fibrinogen <150 mg/dL
Soluble IL-2 receptor >2400 U/mL
Bone marrow examination for hemophagocytosis

Drug-Induced Hypersensitivity:

DRESS syndrome
Stevens-Johnson syndrome/TEN
Drug fever patterns

Autoinflammatory Syndromes:

Adult-onset Still's disease
Familial Mediterranean fever
TNF receptor-associated periodic syndrome

Malignancy-Associated Syndromes:

Tumor fever
Paraneoplastic syndromes
Hemophagocytic syndrome secondary to malignancy

Viral Sepsis: Recognition and Management

Clinical Presentation Patterns

Influenza-like Illness with Sepsis Features:

Rapid onset of high fever, myalgia, headache
Respiratory symptoms predominant
Lymphopenia common
Secondary bacterial infections possible

COVID-19 Sepsis Syndrome:

Progressive respiratory failure
Coagulopathy and thrombotic events
Gastrointestinal involvement
Prolonged viral shedding

Other Viral Causes:

CMV: Immunocompromised hosts, prolonged fever
EBV: Lymphadenopathy, atypical lymphocytes
HSV: CNS involvement, characteristic vesicles
Adenovirus: Respiratory and GI symptoms

Pearl #2: Viral Sepsis Biomarker Pattern

Typical pattern: Low-normal PCT (<0.5 ng/mL), elevated CRP, lymphopenia, elevated LDH, normal neutrophil count or lymphocytosis.

Diagnostic Testing for Viral Sepsis

Molecular Diagnostics:

Respiratory viral PCR panels
Blood viral PCR (CMV, EBV, HSV)
CSF viral PCR when indicated
Stool viral studies for GI presentations

Serological Studies:

IgM antibodies for acute infection
IgG avidity testing
Complement fixation tests

Specialized Testing:

Viral load quantification (CMV, EBV)
Viral culture (limited utility in acute setting)
Antigen detection (influenza, RSV)

Hemophagocytic Lymphohistiocytosis: The Great Mimic

HLH represents a hyperinflammatory syndrome that can closely mimic sepsis, with mortality rates exceeding 50% if unrecognized.

Clinical Recognition

Cardinal Features:

Prolonged fever >38.5°C
Hepatosplenomegaly
Cytopenias affecting ≥2 cell lines
Hypertriglyceridemia and/or hypofibrinogenemia
Elevated ferritin (often >3000 µg/L)
Elevated soluble IL-2 receptor
Hemophagocytosis in bone marrow, lymph nodes, or spleen

Pearl #3: The "Ferritin-Fever Ratio"

Ferritin >3000 µg/L with fever >39°C for >7 days strongly suggests HLH, especially with concurrent cytopenias.

HLH Triggers in Critical Care

Infectious Triggers:

EBV, CMV, other herpesviruses
Mycobacterial infections
Fungal infections
Parasitic infections

Non-Infectious Triggers:

Malignancy (especially T-cell lymphomas)
Autoimmune diseases
Genetic HLH syndromes
Drug reactions

Diagnostic Approach to HLH

HScore Calculator Components:

Temperature >38.5°C: +33 points
Hepatomegaly: +23 points
Splenomegaly: +23 points
Triglycerides >265 mg/dL: +44 points
Fibrinogen <150 mg/dL: +30 points
Ferritin 500-2000 µg/L: +35 points; 2000-6000 µg/L: +50 points; >6000 µg/L: +50 points
AST >30 IU/L: +19 points
Hemophagocytosis on bone marrow: +35 points
Immunosuppression: +18 points

Score Interpretation:

<90: Low probability
90-169: Intermediate probability
169: High probability of HLH

Decision-Making Algorithms

Algorithm 1: Initial Assessment of Culture-Negative Sepsis

Patient with Clinical Sepsis Syndrome + Negative Cultures (48-72h)
                            ↓
Step 1: Review Pre-analytical Factors
- Prior antibiotics? → Consider extended cultures, PCR
- Adequate samples? → Repeat sampling if indicated
                            ↓
Step 2: Biomarker Assessment
- PCT >0.5 ng/mL → Consider bacterial causes
- PCT <0.5 ng/mL + lymphopenia → Consider viral causes
- Ferritin >3000 µg/L → Consider HLH
                            ↓
Step 3: Clinical Pattern Recognition
- Acute respiratory illness → Viral PCR panels
- Subacute fever + travel → Fastidious bacteria/parasites
- Multi-organ dysfunction + cytopenias → HLH evaluation

Algorithm 2: Extended Investigation Strategy

Tier 1 Testing Negative
        ↓
Assess Clinical Trajectory:
- Improving on antibiotics → Probable bacterial (continue treatment)
- Static/worsening → Proceed to Tier 2
        ↓
Tier 2: Advanced Microbiology
- mNGS, specialized cultures, serology
- Response assessment at 48-72h
        ↓
Still Negative + High Clinical Suspicion
        ↓
Tier 3: Non-infectious Evaluation
- HLH workup, autoimmune markers, malignancy screening

Hack #2: The "Antibiotic Challenge Test"

In stable patients with culture-negative sepsis, consider a 48-72 hour antibiotic discontinuation trial while monitoring biomarkers. Rising PCT or clinical deterioration suggests bacterial etiology.

Advanced Diagnostic Technologies

Metagenomic Next-Generation Sequencing (mNGS)

Advantages:

Unbiased detection of all microorganisms
Identification of novel pathogens
Detection of antimicrobial resistance genes
Useful for fastidious and unculturable organisms

Limitations:

High cost and turnaround time
Requires specialized interpretation
Contamination issues
Limited quantitative information

Clinical Applications:

CNS infections with negative conventional testing
Immunocompromised patients
Healthcare-associated infections
Travelers with unusual exposures

Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF)

Applications in Culture-Negative Sepsis:

Rapid identification of slow-growing organisms
Detection of biofilm-associated bacteria
Identification of fastidious pathogens
Quality control for blood culture systems

Point-of-Care Testing

Emerging Technologies:

Rapid PCR platforms (results in 1-2 hours)
Microfluidic devices for bacterial detection
Smartphone-based diagnostic platforms
Biosensors for real-time pathogen detection

Biomarkers in Culture-Negative Sepsis

Traditional Biomarkers

Procalcitonin (PCT):

Bacterial infections: Typically >0.5 ng/mL
Viral infections: Usually <0.5 ng/mL
Non-infectious inflammation: Variable but often <2 ng/mL
Kinetics more important than single values

C-Reactive Protein (CRP):

Non-specific inflammatory marker
Useful for monitoring treatment response
Limited discrimination between bacterial and viral

Pearl #4: Biomarker Kinetics

In bacterial infections, PCT typically peaks at 12-24 hours and falls by 50% daily with appropriate treatment. Persistent elevation suggests ongoing infection or complications.

Emerging Biomarkers

Presepsin (soluble CD14-ST):

Higher specificity for bacterial infections than PCT
Useful in immunocompromised patients
Rapid clearance allows for early treatment monitoring

Neutrophil CD64:

Flow cytometry-based assay
High sensitivity for bacterial infections
Rapid results (within hours)
Less affected by immunosuppression

Host Response Biomarkers:

Interferon-γ-induced protein 10 (IP-10): Viral infections
TRAIL (TNF-related apoptosis-inducing ligand): Viral vs. bacterial
Interleukin-27: Bacterial infections

Antimicrobial Stewardship in Culture-Negative Sepsis

Principles of Antibiotic Management

Initial Empirical Therapy:

Broad-spectrum coverage based on clinical syndrome
Consider local epidemiology and resistance patterns
Account for patient risk factors and comorbidities
Include atypical pathogen coverage when indicated

De-escalation Strategy:

Daily reassessment of antibiotic necessity
Biomarker-guided duration (PCT-guided protocols)
Switch to targeted therapy based on diagnostic results
Consider discontinuation in stable patients with alternative diagnoses

Oyster #2: The "Antibiotic Paradox"

Patients with culture-negative sepsis often receive longer courses of broader-spectrum antibiotics than those with culture-positive infections, leading to increased resistance and adverse effects.

Duration Guidelines

Evidence-Based Recommendations:

Uncomplicated culture-negative sepsis: 5-7 days if clinical improvement
PCT-guided therapy: Stop when PCT <0.5 ng/mL or 80% reduction from peak
Severe sepsis/septic shock: 7-10 days minimum
Immunocompromised hosts: Extended courses may be necessary

Special Situations

Critically Ill Patients:

Maintain broad-spectrum coverage until stabilization
Consider combination therapy for severe presentations
Extended gram-positive coverage for catheter-related infections
Anti-pseudomonal coverage for ventilator-associated pneumonia

Immunocompromised Hosts:

Extended spectrum coverage including fungi
Consideration of atypical and opportunistic pathogens
Longer treatment durations
Prophylactic strategies when appropriate

Clinical Pearls and Practical Tips

Pearl #5: The "48-Hour Rule"

Most true bacterial pathogens will be detected within 48 hours using modern blood culture systems. Exceptions include HACEK organisms, nutritionally variant streptococci, and Mycobacterium species.

Pearl #6: Geographic and Temporal Clustering

New cases of culture-negative sepsis with similar presentations in the same unit or time period should raise suspicion for:

Contaminated medical devices or solutions
Common source outbreaks
Viral epidemics
Laboratory processing issues

Hack #3: The "Reverse PCR Strategy"

When viral PCR is positive but bacterial cultures negative, consider that viral infections can predispose to secondary bacterial infections. Monitor for clinical deterioration and consider bacterial co-infection.

Oyster #3: The "Sampling Bias"

Patients with culture-negative sepsis are more likely to have received antibiotics before culture collection. Always inquire about any antimicrobial use in the preceding 2 weeks, including over-the-counter preparations.

Quality Improvement and System Approaches

Institutional Protocols

Culture Collection Standards:

Minimum 10 mL per blood culture bottle
Two separate venipuncture sites
Proper skin disinfection protocols
Rapid transport to laboratory (<6 hours)

Diagnostic Stewardship:

Guidelines for advanced testing utilization
Cost-effectiveness considerations
Turnaround time optimization
Result interpretation support

Multidisciplinary Approach:

Infectious disease consultation protocols
Pharmacy antimicrobial stewardship involvement
Laboratory medicine collaboration
Critical care team integration

Future Directions and Research

Emerging Technologies

Artificial Intelligence and Machine Learning:

Predictive models for pathogen identification
Automated interpretation of complex diagnostic data
Real-time decision support systems
Pattern recognition for unusual presentations

Rapid Diagnostics:

Next-generation PCR platforms
Digital pathology for tissue diagnosis
Volatile organic compound detection
Metabolomic profiling

Biomarker Development

Novel Host Response Markers:

Circulating microRNAs
Proteomic signatures
Metabolomic profiles
Immune function assays

Pathogen-Specific Markers:

Bacterial DNA fragments
Toxin detection assays
Cell wall components
Virulence factor identification

Case-Based Learning

Case 1: The Traveler with Culture-Negative Sepsis

Presentation: 35-year-old male, recent travel to Southeast Asia, presented with high fever, headache, myalgia, and thrombocytopenia. Blood cultures negative at 48 hours.

Key Features:

Geographic exposure history
Thrombocytopenia with fever
Negative standard cultures

Diagnostic Approach:

Malaria smears and rapid antigen tests
Dengue fever serology and PCR
Typhoid fever testing (blood PCR, serology)
Rickettsial disease serology

Learning Points:

Travel history crucial for differential diagnosis
Vector-borne diseases often culture-negative
Regional disease patterns influence testing strategy

Case 2: The Immunocompromised Host

Presentation: 28-year-old female with SLE on immunosuppression, presenting with fever, hepatosplenomegaly, and pancytopenia. Cultures negative at 72 hours.

Key Features:

Immunocompromised state
Multi-organ involvement
Cytopenias

Diagnostic Approach:

HLH evaluation (HScore, ferritin, sIL-2R)
Viral studies (CMV, EBV, parvovirus B19)
Fungal and mycobacterial cultures
Bone marrow examination

Learning Points:

HLH can mimic sepsis in immunocompromised patients
Multiple pathogen types must be considered
Bone marrow examination may be diagnostic

Conclusion

Culture-negative sepsis represents a complex diagnostic challenge requiring a systematic, evidence-based approach. The key to successful management lies in:

Recognition of clinical patterns that suggest specific etiologies
Strategic use of advanced diagnostics including molecular testing and biomarkers
Consideration of non-infectious mimics such as HLH and autoinflammatory syndromes
Implementation of antimicrobial stewardship principles to optimize outcomes while minimizing resistance
Multidisciplinary collaboration to ensure comprehensive evaluation

As diagnostic technologies continue to evolve, the landscape of culture-negative sepsis will undoubtedly change. However, the fundamental principles of careful clinical assessment, systematic investigation, and judicious antimicrobial use will remain cornerstones of management.

The critical care physician must maintain a high index of suspicion for alternative diagnoses while avoiding the pitfalls of diagnostic anchoring and premature closure. By following the systematic approaches outlined in this review, clinicians can improve diagnostic accuracy, optimize patient outcomes, and contribute to responsible antimicrobial stewardship.

References

Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762-774.
Póvoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect. 2005;11(2):101-108.
Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498.
Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 2001;120(3):955-970.
La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. PLoS One. 2009;4(11):e8041.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol. 2019;14:319-338.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet. 2013;381(9868):774-775.
Puskarich MA, Trzeciak S, Shapiro NI, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med. 2011;39(9):2066-2071.
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.
Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77.
Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012;38(6):940-949.
Tissières P, Torgerson TR, Fleischmann-Struzek C, et al. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8.

Conflicts of Interest: The authors declare no conflicts of interest.

Funding: This work received no specific funding.

Sunday, August 31, 2025